Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
1.
Transpl Infect Dis ; 16(1): 135-40, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24383613

RESUMO

Trichosporon species are rare etiologic agents of invasive fungal infection in solid organ transplant (SOT) recipients. We report 2 well-documented cases of Trichosporon inkin invasive infection in SOT patients. We also conducted a detailed literature review of Trichosporon species infections in this susceptible population. We gathered a total of 13 cases of Trichosporon species infections. Any type of organ transplantation can be complicated by Trichosporon infection. Bloodstream infections and disseminated infections were the most common clinical presentations. Liver recipients with bloodstream or disseminated infections had poor prognoses. Although the most common species was formerly called Trichosporon beigelii, this species name should no longer be used because of the changes in the taxonomy of this genus resulting from the advent of molecular approaches, which were also used to identify the strains isolated from our patients. Antifungal susceptibility testing highlights the possibility of multidrug resistance. Indeed, Trichosporon has to be considered in cases of breakthrough infection or treatment failure under echinocandins or amphotericin therapy. Voriconazole seems to be the best treatment option.


Assuntos
DNA Fúngico/análise , Empiema/imunologia , Rejeição de Enxerto/prevenção & controle , Transplante de Coração , Hospedeiro Imunocomprometido , Imunossupressores/uso terapêutico , Pneumopatias Fúngicas/imunologia , Transplante de Pulmão , Mediastinite/imunologia , Pericardite/imunologia , Trichosporon/genética , Tricosporonose/imunologia , Adulto , Antifúngicos/uso terapêutico , DNA Intergênico/análise , DNA Ribossômico/análise , Farmacorresistência Fúngica , Empiema/diagnóstico , Empiema/tratamento farmacológico , Humanos , Pneumopatias Fúngicas/diagnóstico , Pneumopatias Fúngicas/tratamento farmacológico , Masculino , Mediastinite/diagnóstico , Mediastinite/tratamento farmacológico , Testes de Sensibilidade Microbiana , Pericardite/diagnóstico , Pericardite/tratamento farmacológico , Derrame Pleural/diagnóstico , Derrame Pleural/tratamento farmacológico , Derrame Pleural/imunologia , Pirimidinas/uso terapêutico , Análise de Sequência de DNA , Triazóis/uso terapêutico , Tricosporonose/diagnóstico , Tricosporonose/tratamento farmacológico , Voriconazol , Adulto Jovem
2.
Oral Dis ; 20(3): e36-41, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23656547

RESUMO

OBJECTIVE: To determine the frequency of Candida spp., xerostomia, and salivary flow rate (SFR) in three different groups: patients with OLP (OLP group), patients with oral mucosal lesions other than OLP (non-OLP group), and subjects without oral mucosal lesions (control group). MATERIAL AND METHODS: Xerostomia as well as SFR was investigated in the three groups. Samples for isolation of Candida spp. were collected from OLP lesions (38 patients), non-OLP lesions (28 patients), and healthy subjects (32 subjects). RESULTS: There was no statistically significant difference regarding the frequency of xerostomia and hyposalivation among the three groups (P > 0.05). A higher prevalence for colonization by Candida spp. was found in the healthy subject as compared to that of patients with OLP (P = 0.03) and non-OLP (P = 0.02) groups. Low SFR was not a factor for colonization by Candida spp. CONCLUSIONS: Xerostomia and hyposalivation occur with similar frequency in subjects with and without oral lesions; also, the presence of oral lesions does not increase the susceptibility to colonization by Candida spp. It seems that any study implicating Candida spp. in the malignant transformation of oral lesions should be carried out mostly on a biochemical basis, that is, by testing the capability of Candida spp. to produce carcinogenic enzyme.


Assuntos
Candida/isolamento & purificação , Candidíase/epidemiologia , Candidíase/etiologia , Líquen Plano Bucal/complicações , Líquen Plano Bucal/microbiologia , Xerostomia/epidemiologia , Xerostomia/etiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Adulto Jovem
3.
Mycopathologia ; 176(5-6): 353-7, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23982286

RESUMO

Current knowledge on the natural history of paracoccidioidomycosis states that the chronic form of the disease results from reactivation of quiescent foci established years or decades before during the primary lung infection. Once reactivated, the fungi can disseminate to virtually any organ or system. We present herein two chronic paracoccidioidomycosis patients with a single organ involvement that points to an alternative pathogenesis of the mycosis. These patients suggest that the chronic form may also arise from reactivation of foci not confined to the lungs, due to the early dissemination of yeast cells during the primary infection.


Assuntos
Enteropatias/microbiologia , Enteropatias/patologia , Paracoccidioidomicose/patologia , Colonoscopia , Feminino , Histocitoquímica , Humanos , Intestinos/patologia , Pulmão/diagnóstico por imagem , Microscopia , Pessoa de Meia-Idade , Radiografia Torácica , Tomografia Computadorizada por Raios X
4.
J Eur Acad Dermatol Venereol ; 26(3): 319-24, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21623925

RESUMO

BACKGROUND: Infliximab and etarnecept are now widely used for treating severe psoriasis. However, these drugs, especially infliximab, increased the risk of tuberculosis reactivation. Surprisingly, epidemiological data suggest that the tuberculosis rate in patients taking infliximab in São Paulo State, Brazil, is similar to that of some developed, non-endemic countries. OBJECTIVE: The aim of this study was to better understand the effect of infliximab on Mycobacterium tuberculosis (Mtb) immune responses of psoriasis patients in an endemic setting (Brazil). METHODS: We evaluated the tuberculosis-specific immune responses of severe psoriasis patients and healthy individuals, both tuberculin skin test (TST) positive, in the presence/absence of infliximab. Patients had untreated severe psoriasis, no co-morbidities affecting the immune responses and a TST >10 mm. Healthy TST(+) (>10 mm) individuals were evaluated in parallel. PBMC cultures from both groups were stimulated with different Mycobacterium tuberculosis (Mtb) antigens (ESAT-6, 85B and Mtb lysate) and phytohemagglutinin, with or without infliximab (5 µg/mL). Parameters evaluated were TNF-α, IFN-γ and IL-10 secretion by ELISA, overnight IFN-γ ELISpot and lymphocyte proliferative response (LPR). RESULTS: Infliximab almost abolished TNF-α detection in PBMC supernatants of both groups. It also significantly reduced the LPR to phytohemagglutinin and the Mtb antigens as well as the IFN-γ levels secreted into day 5 supernatants in both groups. There was no concomitant exaggerated IL-10 secretion that could account for the decreases in these responses. ELISpot showed that, contrasting with the central-memory responses above, infliximab did not affect effector-memory INF-γ-releasing T-cell numbers. CONCLUSIONS: Infliximab affected some, but not all aspects of the in vitro antituberculosis immune responses tested. The preserved effector-memory responses, putatively related to exposure to environmental mycobacteria, may help to explain the lower than expected susceptibility to tuberculosis reactivation in our setting.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Mycobacterium tuberculosis/imunologia , Psoríase/tratamento farmacológico , Adulto , Anticorpos Monoclonais/imunologia , Ensaio de Imunoadsorção Enzimática , ELISPOT , Feminino , Humanos , Infliximab , Interferon gama/sangue , Interleucina-10/sangue , Masculino , Psoríase/imunologia , Estatísticas não Paramétricas , Teste Tuberculínico , Fator de Necrose Tumoral alfa/sangue
5.
Biochim Biophys Acta ; 1797(6-7): 698-709, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20226160

RESUMO

With the extraordinary progress of mitochondrial science and cell biology, novel biochemical pathways have emerged as strategic points of bioenergetic regulation and control. They include mitochondrial fusion, fission and organellar motility along microtubules and microfilaments (mitochondrial dynamics), mitochondrial turnover (biogenesis and degradation), and mitochondrial phospholipids synthesis. Yet, much is still unknown about the mutual interaction between mitochondrial energy state, biogenesis, dynamics and degradation. Meanwhile, clinical research into metabolic abnormalities in tumors as diverse as renal carcinoma, glioblastomas, paragangliomas or skin leiomyomata, has designated new genes, oncogenes and oncometabolites involved in the regulation of cellular and mitochondrial energy production. Furthermore, the examination of rare neurological diseases such as Charcot-Marie Tooth type 2a, Autosomal Dominant Optic Atrophy, Lethal Defect of Mitochondrial and Peroxisomal Fission, or Spastic Paraplegia suggested involvement of MFN2, OPA1/3, DRP1 or Paraplegin, in the auxiliary control of mitochondrial energy production. Lastly, advances in the understanding of mitochondrial apoptosis have suggested a supplementary role for Bcl2 or Bax in the regulation of mitochondrial respiration and dynamics, which has fostered the investigation of alternative mechanisms of energy regulation. In this review, we discuss the regulatory mechanisms of cellular and mitochondrial energy production, and we emphasize the importance of the study of rare neurological diseases in addition to more common disorders such as cancer, for the fundamental understanding of cellular and mitochondrial energy production.


Assuntos
Mitocôndrias/metabolismo , Trifosfato de Adenosina/biossíntese , Animais , Núcleo Celular/metabolismo , Metabolismo Energético , Homeostase , Humanos , Modelos Biológicos , Neoplasias/metabolismo , Doenças do Sistema Nervoso/metabolismo , Organelas/metabolismo , Fosforilação Oxidativa , Transdução de Sinais
6.
Transpl Infect Dis ; 13(1): 63-9, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20678090

RESUMO

Leprosy still is an important public health problem in several parts of the world including Brazil. Unlike the diseases caused by other mycobacteria, the incidence and clinical presentation of leprosy seems little affected in immunosuppressed patients. We report the first case, to our knowledge, of a liver transplant patient who developed multi-bacillary leprosy. The patient presented with papules and infiltrated plaques with loss of sensation suggestive of leprosy 3.5 years after living-related liver transplantation for autoimmune hepatitis. A skin biopsy showing non-caseating macrophagic granulomas, neuritis, and intact acid-fast bacilli on Fite-Faraco stain, confirmed the diagnosis of borderline lepromatous leprosy. The donor of the liver did not show any evidence of leprosy. During follow-up, the patient presented 2 episodes of upgrading leprosy type I reactions, 1 mild before leprosy treatment, and 1 moderate 3 months after receiving standard multi-drug treatment (rifampicin, clofazimine, and dapsone). These reactions were accompanied by increase in liver function tests, especially of canalicular enzymes. This reaction occurred despite the patient's triple immunosuppression regimen. The moderate reaction was successfully treated with further immunosuppression (prednisone, 0.5 mg/kg). Currently, the patient is asymptomatic, off leprosy medication, with routine liver transplant follow-up. The dilemmas in diagnosis and management of such a case are discussed and the literature on leprosy in transplant recipients is reviewed.


Assuntos
Glucocorticoides/uso terapêutico , Hansenostáticos/uso terapêutico , Hanseníase Multibacilar/diagnóstico , Hanseníase Multibacilar/tratamento farmacológico , Transplante de Fígado/efeitos adversos , Mycobacterium leprae/efeitos dos fármacos , Clofazimina/uso terapêutico , Quimioterapia Combinada , Humanos , Terapia de Imunossupressão , Hanseníase Multibacilar/microbiologia , Hanseníase Multibacilar/patologia , Masculino , Pessoa de Meia-Idade , Mycobacterium leprae/isolamento & purificação , Prednisona/uso terapêutico , Pele/microbiologia , Pele/patologia , Resultado do Tratamento
7.
Mem Inst Oswaldo Cruz ; 105(1): 25-32, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20209325

RESUMO

The immunopathogenesis of chronic hepatitis C virus (HCV) infection is a matter of great controversy and has been suggested to involve a complex balance between cytokines with pro and anti-inflammatory activity. We investigated the expression of inflammatory cells and cytokines in the liver and serum of 51 chronically HCV infected patients and compared them to data from two sets of normal controls: 51 healthy blood donors and 33 liver biopsies of healthy liver donors. We also assessed the relationship between selected cytokines and cell populations in hepatic compartments and the disease stage. Compared with controls, hepatitis C patients had a greater expression of portal TNF-alpha, TGF-beta and CD4(+) and acinar IFN-gamma, TNF-alpha, IL-1beta and IL-4, as well as a higher serum concentration of IL-2, IL-10 and TGF-beta. Significant positive correlations were found between portal CD4+ and TNF-alpha, portal CD8(+) and TGF-beta, portal CD45(+)RO and TNF-alpha, acinar CD45(+)RO and IFN-gamma and acinar CD57(+) and TGF-beta. In conclusion, we have shown that (i) in this sample of predominantly mild disease, the immune response was associated with a pro-inflammatory response pattern, (ii) CD4(+) T-lymphocytes played a major role in orchestrating the immune response and (iii) these events primarily took place in the portal space.


Assuntos
Citocinas/imunologia , Hepatite C Crônica/imunologia , Adolescente , Adulto , Estudos de Casos e Controles , Feminino , Hepatite C Crônica/patologia , Humanos , Imunidade Celular , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Linfócitos T/imunologia , Adulto Jovem
8.
Int J Biochem Cell Biol ; 40(8): 1543-54, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18207445

RESUMO

Activity defects in respiratory chain complexes are responsible for a large variety of pathological situations, including neuromuscular diseases and multisystemic disorders. Their impact on energy production is highly variable and disproportional. The same biochemical or genetic defect can lead to large differences in clinical symptoms and severity between tissues and patients, making the pathophysiological analysis of mitochondrial diseases difficult. The existence of compensatory mechanisms operating at the level of the respiratory chain might be an explanation for the biochemical complexity observed for respiratory defects. Here, we analyzed the role of cytochrome c and coenzyme Q in the attenuation of complex III and complex IV pharmacological inhibition on the respiratory flux. Spectrophotometry, HPLC-EC, polarography and enzymology permitted the calculation of molar ratios between respiratory chain components, giving values of 0.8:61:3:12:6.8 in muscle and 1:131:3:9:6.5 in liver, for CII:CoQ:CIII:Cyt c:CIV. The results demonstrate the dynamic functional compartmentalization of respiratory chain substrates, with the existence of a substrate pool that can be recruited to maintain energy production at normal levels when respiratory chain complexes are inhibited. The size of this reserve was different between muscle and liver, and in proportion to the magnitude of attenuation of each respiratory defect. Such functional compartmentalization could result from the recently observed physical compartmentalization of respiratory chain substrates. The dynamic nature of the mitochondrial network may modulate this compartmentalization and could play a new role in the control of mitochondrial respiration as well as apoptosis.


Assuntos
Citocromos c/fisiologia , Transporte de Elétrons/fisiologia , Doenças Mitocondriais/tratamento farmacológico , Doenças Mitocondriais/fisiopatologia , Ubiquinona/fisiologia , Animais , Complexo III da Cadeia de Transporte de Elétrons/antagonistas & inibidores , Complexo IV da Cadeia de Transporte de Elétrons/antagonistas & inibidores , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Masculino , Metacrilatos/farmacologia , Mitocôndrias Hepáticas/metabolismo , Mitocôndrias Musculares/metabolismo , Consumo de Oxigênio , Cianeto de Potássio/farmacologia , Ratos , Ratos Wistar , Tiazóis/farmacologia
9.
Curr Top Med Chem ; 18(15): 1333-1348, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30277157

RESUMO

The thermally-dimorphic systemic fungal group includes several important human pathogens: Blastomyces dermatitides, Coccidioides immitis and C. posadasii, Histoplasma capsulatum, Paracoccidioides brasiliensis, P. lutzii, and Talaromyces (Penicillium) marneffei. They usually are geographically restricted and have natural habitats in soil or in plants, and when fungal propagules invade mammalian host by inhalation, they initiate an inflammatory reaction that can result in self-resolution of the infection or cause an acute or chronic disease. In the setting of the AIDS pandemic and the developments in modern medicine, such as immunosuppressive therapy in cancer surgery patients and in transplantation and autoimmune diseases, the incidence of endemic mycoses has progressively increased. Another important factor of the increased incidence of systemic mycoses in certain regions is the progressive devastation of tropical and subtropical forests. In this review, we focus on two of the most important systemic mycoses: paracoccidioidomycosis and histoplasmosis, and their major characteristics in epidemiology, clinical aspects and laboratorial diagnosis.


Assuntos
Antifúngicos/farmacologia , Histoplasma/efeitos dos fármacos , Histoplasmose/diagnóstico , Histoplasmose/tratamento farmacológico , Paracoccidioides/efeitos dos fármacos , Paracoccidioidomicose/diagnóstico , Paracoccidioidomicose/tratamento farmacológico , Antifúngicos/química , Histoplasma/isolamento & purificação , Histoplasmose/epidemiologia , Humanos , Testes de Sensibilidade Microbiana , Paracoccidioides/isolamento & purificação , Paracoccidioidomicose/epidemiologia
10.
Chem Biol Interact ; 160(1): 51-60, 2006 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-16412405

RESUMO

Sa and the Sa/So ratio are very sensitive biomarkers of exposure to fumonisins in several species. We previously demonstrated that increases in Sa and in the Sa/So ratio in serum were less pronounced when ducks ingested fumonisins for more than 7 weeks than when animals were exposed for only 1-2 weeks [S.T. Tran, D. Tardieu, A. Auvergne, J.D. Bailly, R. Babilé, S. Durand, G. Benard, P. Guerre, Serum sphinganine and the sphinganine to sphingosine ratio as biomarker of dietary fumonisins during chronic exposure in ducks, Chem. Biol. Interact., in press]. The aim of this study was to investigate the kinetics of Sa and of the Sa/So in both liver and kidney of ducks that have been previously tested for Sa and the Sa/So ratio in serum. Analysis were performed on treatment days 0, 7, 14, 28 and 77 in five groups of ducks fed fumonisins obtained from an extract of Fusarium verticillioides culture material by daily gavage to obtain an exposure equal to 0, 2, 8, 32 and 128 mg FB1/kg feed. Sa and the Sa/So ratio in tissues were then correlated with Sa and the Sa/So ratio previously obtained in serum. The amounts on sphinganine 1-phosphate (Sa1P) and sphingosine1-phosphate (So1P) in the liver were also investigated. On day 7 of treatment, 2mg/kg FB1 in the feed were sufficient to increase Sa and the Sa/So ratio in liver (by 165 and 148%, respectively) and kidney (by 193 and 104%, respectively). At a rate of 128 mg/kg FB1 in the feed, a very high increase in Sa concentration was observed in both liver and kidney without mortality and/or signs of necrosis (respective increase of 2034 and 3768%). Although the precise mechanism of the resistance of ducks to fumonisin-induced hepatotoxicity is still uncertain, it might be linked to the rate at which the sphingoid bases sphinganine and sphingosine are converted to their 1-phosphate or other metabolite and eliminated from target tissues.


Assuntos
Carcinógenos Ambientais/toxicidade , Fumonisinas/toxicidade , Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Micotoxinas , Esfingosina/análogos & derivados , Esfingosina/metabolismo , Administração Oral , Animais , Biomarcadores/sangue , Carcinógenos Ambientais/farmacocinética , Dieta , Relação Dose-Resposta a Droga , Patos , Fumonisinas/farmacocinética , Rim/metabolismo , Rim/patologia , Fígado/metabolismo , Fígado/patologia , Lisofosfolipídeos/metabolismo , Tamanho do Órgão/efeitos dos fármacos , Testes de Toxicidade/métodos
11.
Chem Biol Interact ; 160(1): 41-50, 2006 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-16413517

RESUMO

Sphinganine concentration (Sa) and sphinganine to sphingosine ratio (Sa/So) are sensitive biomarkers of fumonisin B1 (FB1) exposure in animals and have been proposed to reveal FB1 exposure in humans. They correlate with liver and kidney toxicity and often precede signs of toxicity. However, the use of Sa and Sa/So is confusing during chronic exposure. Indeed, some authors report altered sphingolipids metabolism, whereas others fail to demonstrate significant effect. The aim of this study was to investigate the kinetics of Sa and Sa/So in the serum of ducks over a 77-day exposure to 0, 2, 8, 32 and 128 mg FB1/kg feeds. Serum biochemistry was also investigated to reveal hepatotoxicity. The results obtained indicate that the kinetics of sphingolipids and serum biochemistry are closely linked with the duration of the exposure. After a strong and rapid increase Sa and Sa/So decrease then stabilize. The lowest investigated dose able to determine a detectable effect is 2 mg/kg feeds, the Sa/So ratio being the most sensitive biomarker of FB1 exposure.


Assuntos
Carcinógenos Ambientais/farmacocinética , Fumonisinas/farmacocinética , Micotoxinas , Esfingosina/análogos & derivados , Esfingosina/sangue , Animais , Biomarcadores/sangue , Carcinógenos Ambientais/toxicidade , Testes de Química Clínica , Dieta , Relação Dose-Resposta a Droga , Patos , Fumonisinas/toxicidade , Fígado/efeitos dos fármacos , Fígado/patologia , Testes de Função Hepática , Tamanho do Órgão/efeitos dos fármacos , Testes de Toxicidade/métodos
12.
Poult Sci ; 84(1): 22-8, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-15685938

RESUMO

Partially purified fumonisin B1 (FB1) was orally administrated for 77 d to 5 groups of 8 mule ducks starting at 7 d of age; the concentrations corresponded to 5 diets containing 0, 2, 8, 32, and 128 mg of FB1/kg of feed. No mortality was observed, and no effects on feed consumption and body weight gain were observed at the end of the treatment period. But, surprisingly, FB1 ingested at 32 and 128 mg/kg led to decreased body weight from d 28 to 63 and from d 7 to 63, respectively. FB1 had no effect on the relative weight of heart and breast muscle, whereas a significant increases in the relative weights of gizzard, spleen, and liver were measured in ducks receiving 32 and 128 mg of FB1/kg of feed without evidence of detectable microscopic modification of these organs. FB1 had no significant effect of the serum aspartate aminotransferase and gamma-glutamyltransferase levels but increased serum total protein, cholesterol, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase levels when 128 mg of FB1/kg of feed was given. Serum, liver, and kidney sphinganine to sphingosine ratio was significantly increased in ducks fed 8 to 128 mg of FB1/kg of feed. The biggest increase was observed in kidneys, suggesting that this organ is the most sensitive to detect FB1-induced disruption of sphingolipid metabolism.


Assuntos
Patos/metabolismo , Fumonisinas/toxicidade , Esfingosina/análogos & derivados , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Proteínas Sanguíneas/análise , Peso Corporal/efeitos dos fármacos , Colesterol/sangue , Dieta , Fumonisinas/administração & dosagem , Rim/química , Rim/efeitos dos fármacos , L-Lactato Desidrogenase/sangue , Tamanho do Órgão/efeitos dos fármacos , Esfingosina/análise , Esfingosina/sangue
13.
Microbes Infect ; 1(4): 273-8, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10602660

RESUMO

We investigated the relationship between antibody response to the major Paracoccidioides brasiliensis antigen, a 43-kDa glycoprotein, and the two paracoccidioidomycosis (PCM) clinical presentations, the juvenile and the adult forms. Total immunoglobulin G (IgG), IgG isotypes, and IgA anti-gp43 antibodies were determined by enzyme-linked immunosorbent assay in patients'sera. Juvenile PCM patients had higher (P =.003) IgG anti-gp43 levels than adult form patients. IgG1 subclass levels, however, were comparable between the two clinical forms. Patients with the juvenile form had higher (P <. 001) IgG4, but lower (P =.03) IgG2 levels than patients with the adult form. The IgG4 isotype, regulated by interleukin 4, was found in all juvenile form patients but in only 12% of the adult form patients. In contrast, high levels of the IgG2 isotype, regulated by interferon-gamma, were found in 41% of the adult PCM patients, mainly those with a more benign disease, but in only 12% of the juvenile patients. IgG3 was either absent or detected at low levels. These results demonstrate, for the first time, specific IgG4 antibodies in the humoral immune response of patients with an endemic deep mycosis and suggest that the switch to the IgG subclasses in PCM is regulated by the patients' T-helper subset (Th-1 or Th-2) dominant cytokine profile. A possible role for IgG4 in the immunopathogenesis of the juvenile, more severe form of the disease is discussed. Finally, IgA was found mainly in adult form patients, probably as a result of the chronic mucosal antigenic stimulation characteristic of this form.


Assuntos
Anticorpos Antifúngicos/sangue , Antígenos de Fungos , Proteínas Fúngicas , Glicoproteínas/imunologia , Isotipos de Imunoglobulinas/sangue , Oligossacarídeos/imunologia , Paracoccidioides/imunologia , Paracoccidioidomicose/imunologia , Adolescente , Adulto , Anticorpos Antifúngicos/imunologia , Criança , Contraimunoeletroforese , Citocinas/imunologia , Ensaio de Imunoadsorção Enzimática , Humanos , Imunoglobulina A/sangue , Imunoglobulina A/imunologia , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Isotipos de Imunoglobulinas/imunologia , Células Th1/imunologia , Células Th2/imunologia
14.
Pediatr Infect Dis J ; 13(6): 510-5, 1994 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8078739

RESUMO

This report describes clinical and immunologic features of five illustrative cases of paracoccidioidomycosis in previously healthy children. All had disseminated disease and two of them died despite treatment. The major clinical presentation in four patients was fever and diffuse superficial and intraabdominal adenopathy, with or without hepatosplenomegaly. Other sites were also affected: three patients had multiple osteoarticular lesions, occasionally with intense tissue destruction; two had cutaneous eruptions; two had pericardial effusions; and two had pulmonary involvement, once considered an organ spared in the young. We detected variable lymphocyte responses to mitogens and to Candida albicans antigen and non-responsiveness to Paracoccidioides brasiliensis cell wall antigen. High concentrations of serum immunoglobulins and anti-P. brasiliensis antibodies were present. These immune alterations tended to resolve with treatment, suggesting a reversible nature of the immune defect. We conclude that this mycosis has a high morbidity and mortality in children, which is probably related to an antigen-specific immunodeficiency. Further studies are needed to increase knowledge of this mycosis in children.


Assuntos
Paracoccidioidomicose/imunologia , Paracoccidioidomicose/fisiopatologia , Doença Aguda , Candida albicans/imunologia , Criança , Evolução Fatal , Feminino , Humanos , Imunidade Celular , Hospedeiro Imunocomprometido , Ativação Linfocitária , Masculino , Paracoccidioides/imunologia , Paracoccidioidomicose/diagnóstico , Paracoccidioidomicose/terapia
15.
Am J Trop Med Hyg ; 45(1): 138-45, 1991 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1867346

RESUMO

Peripheral blood mononuclear cells (PBMC) from acute leptospirosis patients with and without acute renal failure were studied in order to investigate the status of cellular immunity in this disease. We analyzed the lymphocyte subsets of leptospirosis patients by immunofluorescence and their responsiveness to the mitogens phytohemagglutinin (PHA) and pokeweed mitogen (PWM). Additionally, we investigated the effect of the patients' sera on normal PBMC proliferative response. We observed a decrease in the CD3+ and CD4+ cell subsets in patients with and without acute renal failure, or in percentage values alone in those who had recovered from renal failure. An increase in the number of B lymphocytes was observed in all patients, compared with controls. This increase in B lymphocytes was seen even in patients who had recovered from renal failure, when the number of CD3+ and CD4+ lymphocytes had already returned to normal levels. The low PHA response observed only with lymphocytes from patients with acute renal failure suggests a suppressive effect. The proliferative response to PWM was comparable to controls, even in the patients with acute renal failure. This latter result and the expansion of the B cell number could be related to leptospiral-derived factor(s). We also showed that sera from patients with and without acute renal failure exerted some inhibitory activity on normal PBMC responses to PHA and PWM. Although the redistribution of lymphocyte subsets and the serum suppressor activity were related to acute renal failure and leptospiral factor(s), we suggest that the cellular immune system was not irreversibly affected, which is compatible with the good prognosis seen in the patients studied.


Assuntos
Leptospirose/imunologia , Adolescente , Adulto , Subpopulações de Linfócitos B , Brasil , Humanos , Imunidade Celular , Contagem de Leucócitos , Leucócitos Mononucleares/imunologia , Pessoa de Meia-Idade , Subpopulações de Linfócitos T
16.
Am J Trop Med Hyg ; 54(1): 7-12, 1996 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-8651374

RESUMO

To characterize the immune dysfunction associated with paracoccidioidomycosis, we studied the in vitro lymphocyte reactivity to phytohemagglutinin (PHA), pokeweed mitogen (PWM), a Candida albicans antigen (CMA), and a Paracoccidioides brasiliensis antigen (PbAg) in 32 patients with the acute and the chronic form of the disease before or during the initial phase of treatment and after clinical cure. We also studied, as controls, 30 healthy individuals, 15 of them immune to P. brasiliensis. Results showed a strong hyporesponsiveness to the PbAg while responses to mitogens and CMA were comparable with those of controls. Patients with the acute form of the disease (usually more severe) had more marked PbAg hyporesponsiveness than those with the chronic form. After patients' clinical cure, PbAg proliferative responses were similar to controls and greater than those seen before pretreatment. Changes in other parameters were also seen in the treated patients; skin test anergy to paracoccidioidin, high levels of anti-P. brasiliensis antibodies, leukocytosis, and eosinophilia. These changes were usually more intense in patients with the acute form of the disease. The post-treatment CD4+, CD8+, and total lymphocyte counts were similar to those of controls. Correlation between these parameters and the lymphoproliferative responses to the various stimuli was only found with PbAg: PbAg responses correlated inversely with eosinophil and anti P. brasiliensis antibody levels. Overall, our results demonstrate an antigen-specific-cellular immunity defect, which is reversible with treatment and possibly related to a T helper cell-2 pattern of immune response during active disease.


Assuntos
Antígenos de Fungos/imunologia , Tolerância Imunológica , Paracoccidioidomicose/imunologia , Adolescente , Adulto , Anticorpos Antifúngicos/sangue , Criança , Humanos , Hipersensibilidade Tardia , Ativação Linfocitária , Pessoa de Meia-Idade
17.
Am J Trop Med Hyg ; 53(2): 189-94, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7677223

RESUMO

Antigen-specific cellular immunity in paracoccidioidomycosis (PCM) has been poorly studied due to lack of standard in vitro lymphocyte proliferation assays. To standardize such an assay, we studied T and B cell responses to a Paracoccidioides brasiliensis cell wall extract (PbAg) in healthy subjects sensitized to either P. brasiliensis [Pb(+)Hc(-)] or to Histoplasma capsulatum [Hc(+)Pb(-)], and in nonsensitized persons. All subjects showed, as expected, a vigorous proliferative response to a control fungal antigen obtained from Candida albicans. Lymphocytes from Pb(+)Hc(-) donors, but not from Pb(-)Hc(-) donors, reacted to PbAg by proliferating in a dose-dependent manner with a maximum reaction after 6-9 days, suggesting a secondary specific immune response. Most activated cells were CD+CD4+ lymphocytes. However, Hc(+)Pb(-) donors' cells reacted with PbAg. Cross-reactivity with H. capsulatum was not unexpected, since both fungi, but not C. albicans, share cell wall immunogenic compounds. An enzyme-linked immunosorbent assay to detect human immunoglobulins (Ig) demonstrated that B cells from Pb(+)Hc(-) donors, but not from Pb(-)Hc(-) ones, reacted with PbAg by secreting high levels of IgG and IgM in 12-day culture supernatants. This secretion was possibly mediated by PbAg-activated CD4+ cells. We believe that analysis of T and B lymphocyte responses to PbAg will be useful in the investigation of the infection-associated immune impairment seen in some PCM patients.


Assuntos
Antígenos de Fungos/imunologia , Linfócitos B/imunologia , Hipersensibilidade Tardia/imunologia , Paracoccidioides/imunologia , Linfócitos T/imunologia , Linfócitos T CD4-Positivos/imunologia , Candida albicans/imunologia , Parede Celular/imunologia , Reações Cruzadas , Relação Dose-Resposta Imunológica , Ensaio de Imunoadsorção Enzimática , Feminino , Histoplasma/imunologia , Humanos , Imunidade Celular , Imunização , Imunoglobulinas/imunologia , Recém-Nascido , Masculino , Paracoccidioides/ultraestrutura
18.
Toxicology ; 163(1): 11-22, 2001 May 28.
Artigo em Inglês | MEDLINE | ID: mdl-11376861

RESUMO

Fusarium moniliforme culture material toxicity containing fumonisin B1 (FB1) was investigated into four groups of five growing ducks, each receiving 0,5,15 or 45 mg/kg FB1 by daily oral administration over 12 days. Treatments did not lead to lethality, but the average body weight gain was slightly retarded in treated versus control animals, without apparent dose relation. A dose-dependent increase of the liver weight with a disorganization of the span and implementation of a microglandular structure in both periportal and centrolobular areas was obtained. In the plasma, together protein, cholesterol, alanine aminotransferase, lactate dehydrogenase, gammaglutamyl transferase and sphinganine to sphingosine ratio (SA/SO) were increased. No sign of apoptosis was present neither in the liver nor in peripheral blood lymphocytes and only moderate oxidative damages were obtained. These results are of interest, because although FB1 increases SA/SO and is hepatotoxic in all investigated species, liver hyperplasia with increased liver weight were obtained in ducks, whereas decreased liver weight and apoptosis are observed in rats. Finally, although ducks appeared resistant to FB1 toxicity in terms of mortality, liver alterations were obtained with only 5 mg/kg per day of FB1 for 12 days. Considering the fact that high levels of FB1 may occur in corn (100-300 mg/kg), liver pathology could have an impact in farming conditions.


Assuntos
Doenças das Aves/induzido quimicamente , Ácidos Carboxílicos/toxicidade , Patos/sangue , Fumonisinas , Fusarium/metabolismo , Fígado/efeitos dos fármacos , Fígado/patologia , Esfingosina/análogos & derivados , Animais , Apoptose/efeitos dos fármacos , Doenças das Aves/patologia , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Ácidos Carboxílicos/metabolismo , Relação Dose-Resposta a Droga , Patos/metabolismo , Fusarium/química , Hiperplasia/induzido quimicamente , Rim/efeitos dos fármacos , Rim/patologia , Fígado/anatomia & histologia , Linfócitos/citologia , Linfócitos/efeitos dos fármacos , Malondialdeído/sangue , Malondialdeído/metabolismo , Tamanho do Órgão/efeitos dos fármacos , Estresse Oxidativo , Esfingosina/sangue
19.
Chem Biol Interact ; 146(1): 61-72, 2003 Jul 25.
Artigo em Inglês | MEDLINE | ID: mdl-12902153

RESUMO

The kinetics of free sphinganine (Sa), sphinganine to sphingosine ratio (Sa/So), proteins, cholesterol, alanine aminotransferase (ALAT) and lactate dehydrogenase (LDH) were investigated in the course of fumonisin B1 (FB1) exposure in ducks (20 growing males divided into four groups of 5 receiving, respectively, a daily dose of 0, 5, 15 or 45 mg/kg FB1 via oral administration over 12 days). Descriptive statistics of these parameters were also studied in a large number of ducks not exposed to mycotoxins and free of known pathology. Although the toxin at the end of the treatment affected all the parameters investigated, only 2 days of treatment appeared necessary to increase free Sa concentrations in serum, whereas 6 days were necessary to detect a significant effect on Sa/So ratio. Significant differences between control and treated ducks were observed after 4 days of treatment for ALAT and LDH and after 6 and 8 days for cholesterol and proteins concentrations. The minimum doses of FB1 required to determine an effect were assessed using three different methods. This approach reveals that FB1 has greater effects when it is ingested at a low dose for a long time than when ingested at a high dose for a short time. Although the minimum toxic dose of FB1 in ducks remains to be determined, this result must be considered in the context of chronic exposure to the toxin, not only in avian populations.


Assuntos
Carcinógenos Ambientais/farmacocinética , Patos , Fumonisinas/farmacocinética , Micotoxinas/farmacocinética , Esfingosina/análogos & derivados , Esfingosina/sangue , Alanina Transaminase/sangue , Animais , Biomarcadores , Proteínas Sanguíneas/análise , Colesterol/sangue , Relação Dose-Resposta a Droga , L-Lactato Desidrogenase/sangue , Masculino
20.
Toxicol Lett ; 121(3): 179-90, 2001 May 19.
Artigo em Inglês | MEDLINE | ID: mdl-11369472

RESUMO

The effects of fumonisin B1 (0, 5, 15 and 45 mg/kg/day), obtained from culture material of Fusarium moniliforme, on drug metabolising enzyme activities were investigated in four groups of five growing ducks by daily oral administration over 12 days. No lethality or sign of toxicosis occurred. The liver and kidney weights were increased, whereas microsomal and cytosolic tissue fractions were unaffected. Although the total microsomal P450 content was unaffected, benzphetamine, ethylmorphine, erythromycin N-demethylases and ethoxyresorufin O-deethylase activities were together increased (respectively by 114, 242, 57 and 27% with 5 mg/kg/day and 1024, 969, 200 and 147% with 45 mg/kg/day). By contrast, aminopyrine and nitrosodimethylamine N-demethylases, methoxyresorufin and pentoxyresorufin O-dealkylases, and UDP-glucuronyltransferase activities were only increased by using 45 mg/kg/day, whereas glutathione S-transferases activities remained unaffected.


Assuntos
Ácidos Carboxílicos/toxicidade , Patos/metabolismo , Fumonisinas , Rim/efeitos dos fármacos , Rim/enzimologia , Fígado/efeitos dos fármacos , Fígado/enzimologia , Aminopirina N-Desmetilase/metabolismo , Animais , Sistema Enzimático do Citocromo P-450/metabolismo , Citocromos b5/metabolismo , Relação Dose-Resposta a Droga , Fusarium/metabolismo , Glucuronosiltransferase/metabolismo , Glutationa Transferase/metabolismo , Isoenzimas/metabolismo , Rim/anatomia & histologia , Fígado/anatomia & histologia , Oxigenases de Função Mista , Tamanho do Órgão/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA